tetano
Editor, Senior Moderator
Nat Commun
. 2024 Mar 29;15(1):2752.
doi: 10.1038/s41467-024-47013-0. Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients
Sara De Biasi[SUP] #[/SUP][SUP] 1 [/SUP], Domenico Lo Tartaro[SUP] #[/SUP][SUP] 2 [/SUP], Anita Neroni[SUP] 2 [/SUP], Moritz Rau[SUP] 2 3 [/SUP], Nikolaos Paschalidis[SUP] 4 [/SUP], Rebecca Borella[SUP] 2 [/SUP], Elena Santacroce[SUP] 2 [/SUP], Annamaria Paolini[SUP] 2 [/SUP], Lara Gibellini[SUP] 2 [/SUP], Alin Liviu Ciobanu[SUP] 2 [/SUP], Michela Cuccorese[SUP] 5 [/SUP], Tommaso Trenti[SUP] 5 [/SUP], Ignacio Rubio[SUP] 3 [/SUP], Francesca Vitetta[SUP] 6 [/SUP], Martina Cardi[SUP] 6 [/SUP], Rafael José Argüello[SUP] 7 [/SUP], Diana Ferraro[SUP] 6 [/SUP], Andrea Cossarizza[SUP] 8 9 [/SUP]
Affiliations
Disease-modifying therapies (DMT) administered to patients with multiple sclerosis (MS) can influence immune responses to SARS-CoV-2 and vaccine efficacy. However, data on the detailed phenotypic, functional and metabolic characteristics of antigen (Ag)-specific cells following the third dose of mRNA vaccine remain scarce. Here, using flow cytometry and 45-parameter mass cytometry, we broadly investigate the phenotype, function and the single-cell metabolic profile of SARS-CoV-2-specific T and B cells up to 8 months after the third dose of mRNA vaccine in a cohort of 94 patients with MS treated with different DMT, including cladribine, dimethyl fumarate, fingolimod, interferon, natalizumab, teriflunomide, rituximab or ocrelizumab. Almost all patients display functional immune response to SARS-CoV-2. Different metabolic profiles characterize antigen-specific-T and -B cell response in fingolimod- and natalizumab-treated patients, whose immune response differs from all the other MS treatments.
. 2024 Mar 29;15(1):2752.
doi: 10.1038/s41467-024-47013-0. Immunosenescence and vaccine efficacy revealed by immunometabolic analysis of SARS-CoV-2-specific cells in multiple sclerosis patients
Sara De Biasi[SUP] #[/SUP][SUP] 1 [/SUP], Domenico Lo Tartaro[SUP] #[/SUP][SUP] 2 [/SUP], Anita Neroni[SUP] 2 [/SUP], Moritz Rau[SUP] 2 3 [/SUP], Nikolaos Paschalidis[SUP] 4 [/SUP], Rebecca Borella[SUP] 2 [/SUP], Elena Santacroce[SUP] 2 [/SUP], Annamaria Paolini[SUP] 2 [/SUP], Lara Gibellini[SUP] 2 [/SUP], Alin Liviu Ciobanu[SUP] 2 [/SUP], Michela Cuccorese[SUP] 5 [/SUP], Tommaso Trenti[SUP] 5 [/SUP], Ignacio Rubio[SUP] 3 [/SUP], Francesca Vitetta[SUP] 6 [/SUP], Martina Cardi[SUP] 6 [/SUP], Rafael José Argüello[SUP] 7 [/SUP], Diana Ferraro[SUP] 6 [/SUP], Andrea Cossarizza[SUP] 8 9 [/SUP]
Affiliations
- PMID: 38553477
- PMCID: PMC10980723
- DOI: 10.1038/s41467-024-47013-0
Disease-modifying therapies (DMT) administered to patients with multiple sclerosis (MS) can influence immune responses to SARS-CoV-2 and vaccine efficacy. However, data on the detailed phenotypic, functional and metabolic characteristics of antigen (Ag)-specific cells following the third dose of mRNA vaccine remain scarce. Here, using flow cytometry and 45-parameter mass cytometry, we broadly investigate the phenotype, function and the single-cell metabolic profile of SARS-CoV-2-specific T and B cells up to 8 months after the third dose of mRNA vaccine in a cohort of 94 patients with MS treated with different DMT, including cladribine, dimethyl fumarate, fingolimod, interferon, natalizumab, teriflunomide, rituximab or ocrelizumab. Almost all patients display functional immune response to SARS-CoV-2. Different metabolic profiles characterize antigen-specific-T and -B cell response in fingolimod- and natalizumab-treated patients, whose immune response differs from all the other MS treatments.